SCHEMBL6599368

SCHEMBL6599368

Nn1cnc2c[c]ccc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6599150 0.84 TDP1 (0.31)
SCHEMBL1418905 0.76 GRM5 (0.40)
SCHEMBL6526827 0.73 KMT2A (0.35)
SCHEMBL9557677 0.72 NPC1 (0.41)
SCHEMBL694905 0.71 HTT (0.62)
SCHEMBL145442 0.70 TDP1 (0.54)
SCHEMBL693867 0.68 TDP1 (0.36)
SCHEMBL695764 0.68 HCAR1 (0.44)
SCHEMBL7805166 0.67 CYP11B1 (0.66)
SCHEMBL668813 0.67 CYP11B1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112789045-A Compositions and methods for treating autism 亚莫制药有限公司 2021-05-11 CN disclosed
EP-1385833-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS Amgen Inc. (US) 2004-02-04 EP disclosed
WO-2002083654-A1 TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS AMGEN INC. (US) 2002-10-24 WO disclosed